Nuvectis Pharma (NASDAQ:NVCT) CEO Buys $250,000.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 12,500 shares of Nuvectis Pharma stock in a transaction on Tuesday, June 30th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the acquisition, the chief executive officer owned 3,688,424 shares of the company’s stock, valued at approximately $73,768,480. This represents a 0.34% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Nuvectis Pharma Price Performance

Shares of Nuvectis Pharma stock opened at $19.57 on Friday. The company has a market capitalization of $519.19 million, a P/E ratio of -14.94 and a beta of -0.24. The business has a 50-day moving average of $12.71 and a two-hundred day moving average of $9.89. Nuvectis Pharma, Inc. has a 1 year low of $5.55 and a 1 year high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a research report on Friday, June 5th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nuvectis Pharma currently has an average rating of “Hold” and an average price target of $39.00.

Institutional Trading of Nuvectis Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after acquiring an additional 6,084 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Nuvectis Pharma in the 2nd quarter valued at about $53,000. Bank of America Corp DE grew its position in shares of Nuvectis Pharma by 417.2% in the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after acquiring an additional 6,909 shares during the period. Deutsche Bank AG increased its stake in shares of Nuvectis Pharma by 3,671.4% during the 4th quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock worth $96,000 after purchasing an additional 12,336 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in shares of Nuvectis Pharma during the 2nd quarter worth about $97,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.